Mizuho Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $12
Mizuho analyst Mara Goldstein initiates coverage on IN8bio (NASDAQ:INAB) with a Buy rating and announces Price Target of $12.
Benzinga’s Top Ratings Upgrades, Downgrades For August 23, 2021
Upgrades
JP Morgan upgraded the previous rating for Pearson PLC (NYSE:PSO) from Neutral to Overweight. The current stock performance of Pearson shows a 52-week-high of $12.38 and a 52-week-low of $6.13. Moreover, at the end of the last trading period, the closing price was at $10.41.
B. Riley Securities Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $19
B. Riley Securities initiates coverage on IN8bio (NASDAQ:INAB) with a Buy rating and announces Price Target of $19.
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
IN8bio Completes Dosing Of First Cohort In Phase 1 Clinical Trial With Allogeneic Gamma Delta T-Cell Therapy In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced completion of